Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Lotus Reports Higher Q1 and New Asthma Drug

publication date: May 22, 2008

Lotus Pharmaceuticals, Inc. announced a 41% increase in revenues in Q1, though net income was up by a smaller 19%. The company booked $11.7 million in sales, while its profits totaled $1 million or 2 cents per share, fully diluted. Earlier this week, Lotus announced it will pay 48 million RMB ($7 million) to buy the patent and production rights to an asthma medicine, Laevo- Bambutero. More details...

Stock Symbol: (OTCBB: LTUS)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital